

Yuliya Pylayeva-Gupta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9316342/publications.pdf>

Version: 2024-02-01

21
papers

3,719
citations

623734

14
h-index

752698

20
g-index

21
all docs

21
docs citations

21
times ranked

7415
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of a combined ultrasound and bioluminescence imaging system with magnetic resonance imaging in orthotopic pancreatic murine tumors. <i>Scientific Reports</i> , 2022, 12, 102.	3.3	5
2	IL-12 Family Cytokines in Cancer and Immunotherapy. <i>Cancers</i> , 2021, 13, 167.	3.7	124
3	IL-35 Detection in B Cells at the mRNA and Protein Level. <i>Methods in Molecular Biology</i> , 2021, 2270, 125-147.	0.9	2
4	Regulatory B cells in cancer. <i>Immunological Reviews</i> , 2021, 299, 74-92.	6.0	75
5	B Cell Receptor Signaling and Protein Kinase D2 Support Regulatory B Cell Function in Pancreatic Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 745873.	4.8	9
6	Pancreatic cancer-associated inflammation drives dynamic regulation of p35 and Ebi3. <i>Cytokine</i> , 2020, 125, 154817.	3.2	9
7	Focused Ultrasound for Immunomodulation of the Tumor Microenvironment. <i>Journal of Immunology</i> , 2020, 205, 2327-2341.	0.8	37
8	Pancreatic Cancer Thrives on Hijacking a Homeostatic Tissue Repair Pathway. <i>Gastroenterology</i> , 2020, 158, 1216-1218.	1.3	0
9	B cell-derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 292-308.	3.4	62
10	Rab27a plays a dual role in metastatic propensity of pancreatic cancer. <i>Scientific Reports</i> , 2020, 10, 7390.	3.3	14
11	Interleukin-23 engineering improves CAR T cell function in solid tumors. <i>Nature Biotechnology</i> , 2020, 38, 448-459.	17.5	145
12	Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. <i>Cancer Cell</i> , 2019, 35, 221-237.e8.	16.8	286
13	IL35 Hinders Endogenous Antitumor T-cell Immunity and Responsiveness to Immunotherapy in Pancreatic Cancer. <i>Cancer Immunology Research</i> , 2018, 6, 1014-1024.	3.4	48
14	KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. <i>Cancers</i> , 2016, 8, 45.	3.7	147
15	Molecular Pathways: Interleukin-35 in Autoimmunity and Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4973-4978.	7.0	33
16	IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia. <i>Cancer Discovery</i> , 2016, 6, 247-255.	9.4	283
17	Wild-Type H- and N-Ras Promote Mutant K-Ras-Driven Tumorigenesis by Modulating the DNA Damage Response. <i>Cancer Cell</i> , 2014, 25, 243-256.	16.8	124
18	Microdissection and Culture of Murine Pancreatic Ductal Epithelial Cells. <i>Methods in Molecular Biology</i> , 2013, 980, 267-279.	0.9	6

#	ARTICLE	IF	CITATIONS
19	MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. Journal of Experimental Medicine, 2012, 209, 1671-1687.	8.5	254
20	Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic Neoplasia. Cancer Cell, 2012, 21, 836-847.	16.8	589
21	RAS oncogenes: weaving a tumorigenic web. Nature Reviews Cancer, 2011, 11, 761-774.	28.4	1,467